
|Articles|April 1, 2004
ROSACEA PHASE III STUDY
Patients with rosacea who were treated with CollaGenex Pharmaceuticals' Periostat (doxycycline hyclate) showed continuous improvement during a 16-week Phase III trial, the firm reported. Among the 134 patients who received Periostat or placebo, Periostat-treated patients experienced a significantly greater reduction in the number of inflammatory lesions, according to a preliminary data analysis.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Proposes Expansion of US Sunscreen Ingredient Standards with Bemotrizinol
2
Transformative Advances This Year and Beyond
3
KT-621 Produces 98% STAT6 Degradation in AD Patients
4
When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria
5



















